A detailed history of Mackenzie Financial Corp transactions in Ardelyx, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 38,292 shares of ARDX stock, worth $183,801. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38,292
Previous 29,304 30.67%
Holding current value
$183,801
Previous $217,000 21.2%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.28 - $7.57 $47,456 - $68,039
8,988 Added 30.67%
38,292 $263,000
Q2 2024

Aug 14, 2024

SELL
$5.89 - $9.31 $4,229 - $6,684
-718 Reduced 2.39%
29,304 $217,000
Q1 2024

May 10, 2024

SELL
$6.05 - $9.74 $1,494 - $2,405
-247 Reduced 0.82%
30,022 $219,000
Q4 2023

Jan 30, 2024

BUY
$3.29 - $6.64 $5,290 - $10,677
1,608 Added 5.61%
30,269 $187,000
Q2 2023

Aug 03, 2023

BUY
$3.23 - $4.95 $92,575 - $141,871
28,661 New
28,661 $97,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $742M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Mackenzie Financial Corp Portfolio

Follow Mackenzie Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.